| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/15/2004 |
3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) 03/22/2004 |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common shares without par value | 61,412 | D | |
| Common shares without par value | 12,633(1) | I | profit sharing trust |
| Common shares without par value | 295(2) | I | by wife for daughter |
| Common shares without par value | 296(2) | I | by wife for daughter |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Option (right to buy)(3) | 02/13/2001 | 02/12/2008 | Common shares | 2,702 | 37 | D | |
| Option (right to buy)(3) | 05/17/1999 | 04/28/2004 | Common shares | 628 | 47.58 | D | |
| Option (right to buy)(3) | 05/17/1999 | 12/31/2004 | Common shares | 1,880 | 47.58 | D | |
| Option (right to buy)(3) | 02/12/2000 | 02/11/2009 | Common shares | 3,667 | 45.22 | D | |
| Option (right to buy)(3) | 02/12/2001 | 02/11/2009 | Common shares | 3,667 | 45.22 | D | |
| Option (right to buy)(3) | 02/12/2002 | 02/11/2009 | Common shares | 3,666 | 45.22 | D | |
| Option (right to buy)(3) | 02/11/2002 | 02/10/2010 | Common shares | 4,833 | 34.7 | D | |
| Option (right to buy)(3) | 02/11/2003 | 02/10/2010 | Common shares | 4,833 | 34.7 | D | |
| Option (right to buy)(3) | 02/09/2002 | 02/08/2011 | Common shares | 4,834 | 48.36 | D | |
| Option (right to buy)(3) | 02/09/2003 | 02/08/2011 | Common shares | 4,833 | 48.36 | D | |
| Option (right to buy)(3) | 02/09/2004 | 02/08/2011 | Common shares | 4,823 | 48.36 | D | |
| Option (right to buy)(3) | 07/09/2002 | 07/08/2011 | Common shares | 5,000 | 47.47 | D | |
| Option (right to buy)(3) | 07/09/2003 | 07/08/2011 | Common shares | 5,000 | 47.47 | D | |
| Option (right to buy)(3) | 07/09/2004 | 07/08/2011 | Common shares | 5,000 | 47.47 | D | |
| Option (right to buy)(3) | 06/22/2002 | 02/13/2007 | Common shares | 5,150 | 55.6 | D | |
| Option (right to buy)(3) | 06/22/2002 | 04/27/2005 | Common shares | 3,073 | 55.6 | D | |
| Option (right to buy)(3) | 06/22/2002 | 02/10/2010 | Common shares | 3,727 | 55.6 | D | |
| Option (right to buy)(3) | 06/22/2002 | 02/12/2008 | Common shares | 6,289 | 55.6 | D | |
| Option (right to buy)(3) | 02/15/2003 | 02/14/2012 | Common shares | 16,667 | 57.06 | D | |
| Option (right to buy)(3) | 02/15/2004 | 02/14/2012 | Common shares | 16,666 | 57.06 | D | |
| Option (right to buy)(3) | 02/15/2005 | 02/14/2012 | Common shares | 16,667 | 57.06 | D | |
| Option (right to buy)(3) | 02/14/2004 | 02/13/2013 | Common shares | 20,000 | 35.36 | D | |
| Option (right to buy)(3) | 02/14/2005 | 02/13/2013 | Common shares | 20,000 | 35.36 | D | |
| Option (right to buy)(3) | 02/14/2006 | 02/13/2013 | Common shares | 20,000 | 35.36 | D | |
| Option (right to buy)(3) | 11/30/2003 | 02/08/2006 | Common shares | 1,939 | 43.55 | D | |
| Option (right to buy)(3) | 11/30/2003 | 02/13/2007 | Common shares | 2,650 | 43.55 | D | |
| Option (right to buy)(3) | 02/20/2005 | 02/19/2014 | Common shares | 10,000 | 43.66 | D | |
| Option (right to buy)(3) | 02/20/2006 | 02/19/2014 | Common shares | 10,000 | 43.66 | D | |
| Option (right to buy)(3) | 02/20/2007 | 02/19/2014 | Common shares | 10,000 | 43.66 | D | |
| Explanation of Responses: |
| 1. Balance in the Abbott Laboratories Stock Retirement Trust as of March 17, 2004. |
| 2. Reporting person disclaims beneficial ownership of shares held by his daughters. |
| 3. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. |
| John A. Berry, Attorney-in-Fact for Holger A. Liepmann | 03/22/2004 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
Exhibit 24
POWER OF ATTORNEY
The undersigned constitutes and appoints JOSE M. DE LASA, LAURA J. SCHUMACHER, JOHN A. BERRY and DEBORAH K. KOENEN, and each of them individually, as the undersigned’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned’s name, place and stead, to sign any and all Securities and Exchange Commission (“SEC”) statements of beneficial ownership of securities on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.
A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned revokes such authorization by written instructions to the attorney-in-fact.
Dated: March 15, 2004
|
|
/s/ Holger A. Liepman |
|
|
Signature of Reporting Person |
|
|
Holger A. Liepman |
|
|
Senior Vice President |
|
|
Name and Title |
|
|
|
|
|
|
|
|
Abbott Laboratories |
|
|
100 Abbott Park |
|
|
Abbott Park, IL 60064-6400 |